Display options
Share it on

Biomed Rep. 2016 May;4(5):567-572. doi: 10.3892/br.2016.619. Epub 2016 Feb 29.

Correlation between lung neoplasm and serum level of osteopontin: A meta-analysis.

Biomedical reports

Dan Li, Wang Qian, Ruo Ran Li, Jinghao Zhang, K E Li, Yanmin Wu

Affiliations

  1. Department of Respiratory Medicine, Xuzhou Central Hospital, The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou, Jiangsu 221009, P.R. China.
  2. Department of Hematology, Xuzhou Central Hospital, The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou, Jiangsu 221009, P.R. China.

PMID: 27123248 PMCID: PMC4840616 DOI: 10.3892/br.2016.619

Abstract

The aim of this meta-analysis was to evaluate the clinical significance of serum osteopontin (OPN) levels in lung neoplasm in patients to establish a novel diagnostic score model. Articles were identified by searching the PubMed, Web of Science, Google Scholar, China National Knowledge Infrastructure, and Wang Fang databases. Studies identified were pooled, and the standardized mean difference (SMD) and its corresponding 95% confidence interval (CI) were calculated. Subgroup analyses and publication bias detection were also conducted. Version 12.0 STATA software was used for statistical analysis. A final analysis of 1,327 subjects together (740 patients with lung neoplasms and 587 controls) was performed from 10 clinical case-control studies. The meta-analysis results showed a positive association between serum OPN levels and lung neoplasm (SMD=5.59, 95% CI: 1.85-3.32, P<0.001). The subgroup analysis by ethnicity detected that high levels of serum OPN may be the main risk factor for lung neoplasms in Asians (SMD=1.76, 95% CI: 1.24-2.29, P<0.001), but not in Caucasians (P=0.072). In conclusion, the present meta-analysis indicated that serum OPN levels were generally elevated in lung neoplasm patients, and thus, serum levels of OPN may be useful in diagnosing lung neoplasm in certain population groups.

Keywords: lung neoplasm; meta-analysis; osteopontin

References

  1. Tuberc Respir Dis (Seoul). 2013 Sep;75(3):104-10 - PubMed
  2. Acta Cardiol. 2011 Apr;66(2):197-202 - PubMed
  3. Acta Histochem. 2014 Jan;116(1):222-9 - PubMed
  4. Ann Thorac Surg. 2013 Dec;96(6):1943-51 - PubMed
  5. Tumour Biol. 2014 Dec;35(12):11799-808 - PubMed
  6. J Obstet Gynaecol Res. 2013 Nov;39(11):1518-25 - PubMed
  7. Mol Clin Oncol. 2015 Mar;3(2):357-362 - PubMed
  8. Rev Bras Cir Cardiovasc. 2011 Apr-Jun;26(2):173-82 - PubMed
  9. Bioorg Med Chem Lett. 2015 May 1;25(9):1956-60 - PubMed
  10. Clin Cancer Res. 2006 Jan 15;12(2):323-7 - PubMed
  11. Chin Med J (Engl). 2013;126(9):1683-8 - PubMed
  12. Clin Cancer Res. 2001 Dec;7(12):4060-6 - PubMed
  13. CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300 - PubMed
  14. Med Oncol. 2010 Jun;27(2):332-8 - PubMed
  15. J Clin Invest. 2009 Jun;119(6):1583-94 - PubMed
  16. J Cell Commun Signal. 2009 Dec;3(3-4):311-22 - PubMed
  17. Scand J Clin Lab Invest. 2011 Dec;71(8):690-4 - PubMed
  18. Curr Atheroscler Rep. 2009 May;11(3):206-13 - PubMed
  19. Lung Cancer. 2007 Sep;57(3):373-80 - PubMed
  20. JAMA. 2006 Feb 8;295(6):676-80 - PubMed
  21. Bioinformatics. 2005 Sep 15;21(18):3672-3 - PubMed
  22. J Cancer Res Clin Oncol. 2015 Aug;141(8):1371-8 - PubMed
  23. Stat Med. 2012 Dec 20;31(29):3805-20 - PubMed
  24. BMC Cancer. 2013 Nov 11;13:540 - PubMed
  25. CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29 - PubMed
  26. J Clin Oncol. 2010 Feb 20;28(6):936-41 - PubMed
  27. J Cell Mol Med. 2009 Aug;13(8B):1706-18 - PubMed
  28. J Thorac Oncol. 2009 Jul;4(7):792-801 - PubMed
  29. J Mol Histol. 2014 Oct;45(5):533-40 - PubMed
  30. Clin Cancer Res. 2005 Jul 1;11(13):4646-52 - PubMed
  31. Am J Clin Pathol. 2012 Jun;137(6):971-7 - PubMed
  32. Asian Pac J Cancer Prev. 2014;15(1):29-32 - PubMed
  33. Int J Clin Exp Med. 2014 Dec 15;7(12):4616-26 - PubMed

Publication Types